Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Novartis AG — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.54 (market cap $21.65M), while Novartis AG trades at $150.12 (market cap $288.65B). The key difference: Novartis AG is far larger — about 13332.6× Avalanche Treasury Corporation Class A Common Stock's market cap, and Novartis AG pays a 3.15% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| AVAT | NVS | |
|---|---|---|
Market Cap | $21.65M | $288.65B |
Sector | Financials | Health |
52-Week High | $10.75 | $168.62 |
52-Week Low | $0.51 | $113.50 |
Enterprise Value | $21.65M | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT stock trades at $0.506, down 6.3% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a low P/E of 12 and P/B of 0.4, but negative cash flow from operations at -$930,710 in 2025. Recent Nasdaq listing news highlights its role as an operating company and digital asset treasury focused on capital allocation across the Avalanche economy.
The outlook remains cautious due to negative operational cash flow and bearish technical indicators. Investment opportunity lies in the discounted valuation multiples, while risks include sustained cash burn and competitive pressures in treasury management services. Market sentiment is neutral with recent media coverage of the Nasdaq debut.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
